Funding round
NewLimit Series B
NewLimit, which works in epigenetic reprogramming medicine development in South San Francisco, raised $130M in a Series B round announced on 6 May 2025, led by Kleiner Perkins. 8 firms took part, 3 of them already investors. It is NewLimit's second venture round on record; the one before was a Series A in May 2023.
$130M
Amount raised
Not disclosed
Post-money valuation
8
Investors
1 lead
Valuation
What this round says about the price
NewLimit did not disclose a valuation in this round. It came 24 months after NewLimit's Series A. It is 20% of the $650M NewLimit has raised in the venture rounds on record. NewLimit raised again 5 months later: a Growth round of $45M in Oct 2025, at $1.62B post-money.
NewLimit's funding rounds
NewLimit has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
Kleiner Perkins led the round with 7 other firms. Dimension, Founders Fund and Brian Armstrong had backed NewLimit before.
Lead investor
- Kleiner Perkins backs 285 venture-backed companies new investor
Also in the round
- Nat Friedman/Daniel Gross new investor
- Khosla Ventures backs 396 venture-backed companies new investor
- backs 55 venture-backed companies new investor
- Valor backs 143 venture-backed companies new investor
- backs 24 venture-backed companies existing investor
- Founders Fund backs 368 venture-backed companies existing investor
- Brian Armstrong existing investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development.
- Product development
Comparable rounds
How it compares
107 Series B rounds in Biotechnology within a year either side disclosed an amount; the median was $60M, and this round was 2.2 times the median. The closest in time, other companies' Series B rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 13 May 2025 | $147M | not disclosed | Jeito and Forbion |
| Biotechnology | 27 May 2025 | $130M | not disclosed | Novo Holdings |
| Biotechnology | 6 May 2025 | $45M | not disclosed | Kurma Partners and Angelini Ventures |
| Biotechnology | 13 May 2025 | $26M | not disclosed | European Innovation Council (EIC) Fund and Lifeline Ventures |
| Biotechnology | 1 Apr 2025 | $155M | not disclosed | Venrock and Forbion |
| Biotechnology | 11 Jun 2025 | $135M | not disclosed | EQT and Sanofi Ventures |
| Biotechnology | 24 Apr 2025 | $70M | not disclosed | Forbion and Sanofi Ventures |
| Biotechnology | 18 Jun 2025 | $66M | not disclosed | Regeneron Ventures and Deerfield |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did NewLimit raise in its Series B round?
NewLimit raised $130M in its Series B round, announced in May 2025.
Who led NewLimit's Series B round?
Kleiner Perkins led it, with Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, Valor and Dimension and 2 more.
What was NewLimit's valuation at the Series B round?
It was not disclosed.
How does it compare with other Series B rounds in Biotechnology?
107 Series B rounds in Biotechnology within a year either side disclosed an amount; the median was $60M, and this round was 2.2 times the median.
Did NewLimit raise again after this round?
Yes: a Growth round in Oct 2025 of $45M at $1.62B post-money.